(NASDAQ: PBYI) Puma Biotechnology's forecast annual revenue growth rate of 0.18% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 126.58%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.32%.
Puma Biotechnology's revenue in 2025 is $232,709,000.On average, 1 Wall Street analysts forecast PBYI's revenue for 2025 to be $10,737,712,278, with the lowest PBYI revenue forecast at $10,737,712,278, and the highest PBYI revenue forecast at $10,737,712,278. On average, 1 Wall Street analysts forecast PBYI's revenue for 2026 to be $11,704,662,329, with the lowest PBYI revenue forecast at $11,704,662,329, and the highest PBYI revenue forecast at $11,704,662,329.
In 2027, PBYI is forecast to generate $12,334,073,349 in revenue, with the lowest revenue forecast at $12,334,073,349 and the highest revenue forecast at $12,334,073,349.